National Bank of Canada’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

National Bank of Canada’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-31	Closed	-$1.2K	–	2981
2025 Q3	$1.2K	Buy	+31	New	+$1.12K	﹤0.01%	2636
2024 Q3	–	Sell	-75	Closed	-$3.1K	–	2878
2024 Q2	$3.1K	Sell	75 -15	-17%	-$627	﹤0.01%	2357
2024 Q1	$3.74K	Sell	90 -63	-41%	-$2.87K	﹤0.01%	2366
2023 Q4	$7.1K	Buy	153 +13	+9%	+$530	﹤0.01%	2233
2023 Q3	$5.52K	Buy	140 +50	+56%	+$2.28K	﹤0.01%	2328
2023 Q2	$4.35K	Buy	90 +75	+500%	+$3.75K	﹤0.01%	2368
2023 Q1	$737	Hold	15	–	–	﹤0.01%	2564
2022 Q4	$758	Hold	15	–	–	﹤0.01%	2610
2022 Q3	$1K	Hold	15	–	–	﹤0.01%	2587
2022 Q2	$1K	Hold	15	–	–	﹤0.01%	2680
2022 Q1	$1K	Buy	+15	New	+$946	﹤0.01%	2777

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

USCWA

U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

National Bank of Canada's GNOM Position: Q4 2025 in Review

National Bank of Canada sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2025, closing a stake of 31 shares — an estimated $1.2K sold.

National Bank of Canada first reported a position in GNOM in Q1 2022 and held it in 11 quarters. The position peaked at $7.1K in Q4 2023. 40 funds tracked by Wall St. Rank hold GNOM as of Q4 2025.

National Bank of Canada reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2025 after selling out during the quarter.
National Bank of Canada sold 31 Global X Genomics & Biotechnology ETF shares in Q4 2025, an estimated $1.2K.
National Bank of Canada first reported a position in Global X Genomics & Biotechnology ETF in Q1 2022 and held it in 11 quarters.
National Bank of Canada's Global X Genomics & Biotechnology ETF position peaked at $7.1K in Q4 2023.
40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2025.

Based on National Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.